Sen-Jam Pharmaceutical Engages Destum Partners to Source Strategic Partnerships for SJP-001 & SJP-002C

HUNTINGTON, N.Y., Feb. 10, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a pioneering biotech company dedicated to innovative anti-inflammatory solutions, is pleased to announce its engagement with Destum Partners, a leading advisory firm specializing in biopharma transactions. This strategic collaboration will focus on securing licensing, co-development, and potential M&A opportunities for Sen-Jam's two lead assets, SJP-001 (Overindulgence of Food and Alcohol) and SJP-002C (COVID-19/Upper Respiratory Infections).

Strategic Growth Through Partnerships

This engagement with Destum Partners aligns with Sen-Jam's mission to bring groundbreaking treatments to market while maximizing shareholder value. Key objectives of the collaboration include:

• Identifying and securing strategic licensing and co-development partners to accelerate commercialization.
• Leveraging Destum Partners' extensive industry network across Big Pharma, mid-sized biotech, and consumer health companies.
• Exploring potential M&A transactions to enhance company growth and investor returns.
• Executing a structured transaction process, including outreach, due diligence, valuation modeling, term-sheet negotiations, and deal closure.

Investor Benefits: Fractional Royalty Rights (FRR) on SJP-001

A critical component of this initiative is its direct impact on Sen-Jam's Fractional Royalty Right (FRR) program. Investors participating in the FRR program stand to benefit from licensing revenue generated by SJP-001. A successful licensing agreement would initiate royalty-based revenue streams, with the first investor royalty distributions targeted within 6-12 months post-licensing. This structured approach ensures tangible financial benefits for FRR holders, tying investment success to Sen-Jam's commercial achievements.

Why Destum Partners?

Destum Partners brings an impressive track record of over $5.0 billion in completed transactions and 80+ years of combined experience in pharmaceutical and healthcare deal-making. Their expertise in valuation modeling, strategic advisory services, and transaction execution will be instrumental in securing optimal partnerships for SJP-001 and SJP-002C.

"We are thrilled to be partnering with Sen-Jam Pharmaceutical at such a pivotal moment in their journey," said Matt Vanderberg, Managing Director & Partner at Destum Partners. "Their innovative approach to inflammation management has the potential to redefine patient care, and we look forward to leveraging our expertise to secure the right partners to bring these groundbreaking therapeutics to market."

Next Steps & Strategic Milestones

Destum Partners has already initiated a formal transaction process, beginning with the completion of the Market Analysis and Valuation for SJP-001 and SJP-002C in 2024. Key upcoming milestones include:

• BIO-Europe Spring – March 2025 (Milan)
• BIO International – June 2025 (Boston)
• BIO-Europe Fall – November 2025 (Vienna)

These events, coupled with Destum Partners' extensive industry network, provide vital opportunities for discussions, due diligence, and negotiations with potential strategic partners.

Maximizing Investor Value & Commercial Impact

This partnership underscores Sen-Jam's commitment to delivering long-term shareholder value by advancing SJP-001 and SJP-002C toward commercialization through strategic collaborations. By engaging Destum Partners, Sen-Jam is accelerating its path to market, unlocking new revenue opportunities, and positioning itself as a leader in the next generation of anti-inflammatory therapeutics.

Sen-Jam Pharmaceutical will continue to update stakeholders as discussions progress, milestones are achieved, and pivotal licensing opportunities materialize. With each strategic step, the company solidifies its trajectory toward market success and capital return to investors.

"We are ecstatic to see our therapeutics moving closer to commercialization, and to create significant value for our investors and the broader healthcare community," said Jim Iversen, Co-Founder/CEO at Sen-Jam Pharmaceutical.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is committed to revolutionizing inflammation treatment with its Pleiotropic Anti-Inflammatory Remedies (PAIR) technology, targeting mast cell modulation for superior patient outcomes. Sen-Jam delivers precision therapies that work in harmony with the body's immune system to mitigate systemic risks associated with chronic inflammation while supporting long-term health and vitality. Sen-Jam aims to disrupt traditional approaches to inflammation management and redefine pharmaceutical care. To learn more visit wefunder.com/senjam.

About Destum Partners

Destum Partners is a premier life sciences advisory firm specializing in M&A, licensing, and strategic partnerships. With extensive expertise in biopharma deal-making, Destum Partners supports companies in achieving transformative growth through strategic transactions.

CONTACT INFORMATION:

Sen-Jam Pharmaceutical

Christine Leonard

781-913-1902

View original content:https://www.prnewswire.com/news-releases/sen-jam-pharmaceutical-engages-destum-partners-to-source-strategic-partnerships-for-sjp-001--sjp-002c-302372329.html

SOURCE Sen-Jam Pharmaceutical